60 Degrees Pharmaceuticals (SXTP) – Analysts’ Recent Ratings Changes

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has recently received a number of price target changes and ratings updates:

• 11/19/2025 – 60 Degrees Pharmaceuticals had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – 60 Degrees Pharmaceuticals was upgraded by analysts at Zacks Research to a “hold” rating.
• 11/14/2025 – 60 Degrees Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
• 11/13/2025 – 60 Degrees Pharmaceuticals had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – 60 Degrees Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – 60 Degrees Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.